10-Q quarterly report · filed Nov 2, 2026

RECURSION PHARMACEUTICALS, INC. (RXRX) Q3 2026 10-Q Quarterly Report

Short answer

RECURSION PHARMACEUTICALS, INC. (RXRX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 258.5% year over year) with net income of −$119M.

Q3 2026 key financials · XBRL

Revenue
$19M
+258.5% YoY · +141.8% QoQ
Net income
−$119M
+26.6% YoY · +9.1% QoQ
Operating margin
-664.0%
EPS (diluted)
−$0.22
+38.9% YoY · +12.0% QoQ

Source: XBRL data from the RECURSION PHARMACEUTICALS, INC. (RXRX) Q3 2026 10-Q on SEC EDGAR. USD.

RECURSION PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $18.6M, up over 100% YoY from $5.2M, driven by a $10.0M Sanofi milestone
  • Net loss $119.0M vs $162.3M YoY, with operating loss $123.2M vs $172.2M
  • Best R&D performer: REC-4881 spending $5.8M, up over 100% YoY; worst: internal and partnered discovery, $8.7M, down 75%
  • Cash, equivalents and restricted cash $561.5M vs $753.9M at December 31, 2025; operating cash use $264.5M
  • Registrational REC-4881 trial anticipated in second half of 2027; additional financing expected in the future

Risk Factors

  • No material changes disclosed from the 2025 Annual Report risk factors
  • Key carried-forward risk: common stock investment involves a high degree of risk
  • Detailed risks remain in Part I, Item 1A of the 2025 Annual Report

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other RECURSION PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.